...timelines related to the company's research. Tracon Inc. (NASDAQ:TCON) returned rights to MAP3K14-targeting program TRC694 (JNJ-64290694...

...models of liver disease. Johnson & Johnson and Tracon Pharmaceuticals Inc. have the MAP3K14 inhibitor TRC694...

...unit granted Tracon exclusive, worldwide development rights to TRC253 (formerly JNJ-63576253 ) and TRC694 (formerly JNJ-64290694...
...to reacquire TRC694 up through completion of a proof-of-concept trial. If Tracon continues development of TRC694...
...eligible for up to $60 million in development and regulatory milestones, plus low single-digit royalties. TRC694...